Aquestive Therapeutics AQST
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 45th percentile, 5-year average -6.3x
Below its usual level · 35th percentile, 5-year average -17.2x
Above its usual level · 80th percentile, 5-year average 14.2x
#4494 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -6.94 | – | -17.20 | 35% (cheaper than usual) | – |
| PE | -6.02 | -6.76 | -6.32 | 45% (cheaper than usual) | – |
| PS | 10.06 | 8.90 | 14.20 | 80% (pricier than usual) | #4494 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AQST.
Sign in to join the discussion.